Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
07:00am, Thursday, 04'th Jan 2024
JENA, Germany, Jan. 04, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today toplin
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
11:18am, Friday, 01'st Dec 2023
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
11:17am, Tuesday, 28'th Nov 2023
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Monday, 06'th Nov 2023
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
07:30am, Monday, 06'th Nov 2023
JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that t
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
07:30am, Wednesday, 01'st Nov 2023
JENA, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today fina
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
07:00am, Monday, 11'th Sep 2023
JENA, Germany, Sept. 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today its t
InflaRx: Small German Company Targeting A Rare Indication
05:31pm, Wednesday, 06'th Sep 2023
InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
03:47pm, Friday, 01'st Sep 2023
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
JENA, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that t
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
07:30am, Thursday, 10'th Aug 2023
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States
Why InflaRx Stock Skyrocketed This Week
10:21am, Friday, 07'th Apr 2023
InflaRx stock has soared on news that the company's Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic will be priced above $20,000 per treatment course.
InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injection
03:51pm, Wednesday, 05'th Apr 2023
The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV's monoclonal antibody for the treatment of hospitalized Covid-19 patients, sending the company's stoc
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
12:12pm, Wednesday, 05'th Apr 2023
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
Why Shares of InflaRx Are Soaring Wednesday
11:57am, Wednesday, 05'th Apr 2023
InflaRx is a clinical-stage biotech that focuses on anti-inflammation therapies. Its lead therapy is also seen as a treatment for several skin disorders.
